安必平收盘下跌3.83%，滚动市盈率1188.05倍，总市值26.58亿元

Company Overview - Anbiping's closing price on July 2 was 28.41 yuan, down 3.83%, with a rolling PE ratio of 1188.05 times and a total market value of 2.658 billion yuan [1] - The company operates in the medical device industry, focusing on tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] Financial Performance - For Q1 2025, Anbiping reported revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1] Shareholder Information - As of March 31, 2025, Anbiping had 10,309 shareholders, an increase of 4,393 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 51.29 times, with a median of 37.02 times, placing Anbiping at the 122nd position in the industry ranking [1][2] - Other companies in the industry have significantly lower PE ratios, with the highest being 18.76 times for Antu Biology, indicating a substantial valuation gap [2]